ACE Inhibitors News and Research

RSS

ACE inhibitors act to reduce hypertension by interfering with the conversion of angiotensin I to artery-constricting angiotensin II. Blocking the production of angiotensin II results in arterial vasodilation and an accompanying reduction in blood pressure. ACE inhibitors currently are recommended as first-line therapy for hypertension in certain patient populations, because of their safety and efficacy.

Sinobiopharma's solid dosage Perindopril production facility receives Chinese SFDA approval

Sinobiopharma, Inc. is pleased to announce that its production facility for solid dosage Perindopril has passed the required Chinese State Food and Drug Administration (SFDA) inspection and is now approved for production and marketing.

27 Jan 2010

New issue from Annals of Internal Medicine

Prescriptions of some opioids, such as oxycodone, have increased significantly over the past decade. As long-term opioid therapy for chronic noncancer pain becomes more common, the deaths associated with opioids increase.

19 Jan 2010

High blood pressure drugs may be useful in preventing and treating diabetic retinopathy

Scientists in Massachusetts are reporting new evidence that certain high blood pressure drugs may be useful in preventing and treating diabetic retinopathy, the leading cause of vision loss in people with diabetes. The study, the largest to date on proteins in the retina, could lead to new ways to prevent or treat the sight-threatening disease, they say.

7 Jan 2010

Authors explain why health care reform initiative should include CER

The current health care reform bills approved by the House and the Senate seek to expand health insurance coverage while containing costs; however, the proposed policy changes are not guaranteed to improve health for individuals or society, according to a "Perspective" article by faculty of Weill Cornell Medical College in the Jan. 6 New England Journal of Medicine.

7 Jan 2010

American Diabetes Association recommends A1C test for diagnosing diabetes and identifying pre-diabetes

The American Diabetes Association's new Clinical Practice Recommendations being published as a supplement to the January issue of Diabetes Care call for the addition of the A1C test as a means of diagnosing diabetes and identifying pre-diabetes. The test has been recommended for years as a measure of how well people are doing to keep their blood glucose levels under control.

29 Dec 2009

Alternative therapy for hypertension

New research from the Northwestern University Feinberg School of Medicine has found that an alternative therapy may be possible for treating some types of hypertension using an enzyme called ACE2.

18 Dec 2009

Free medications to people after heart attack will increase length of their life

Providing free medications to people after heart attack could add years to patients' lives at a relatively low cost for provincial governments, according to a new study by researchers at St. Michael's Hospital in Toronto.

1 Dec 2009

European Commission approves MICARDIS medication for CV protection

MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.

27 Nov 2009

MICARDIS receives Health Canada approval to reduce the risk of non-fatal stroke

MICARDIS(R) (telmisartan) has received Health Canada approval to reduce the risk of non-fatal stroke or non-fatal myocardial infarction in patients 55 years or older at high risk of developing major cardiovascular events who cannot tolerate an angiotensin converting enzyme (ACE) inhibitor.

26 Nov 2009

Carvedilol in combination with ACE inhibitors may benefit cardiac patients

In a new study, researchers report that a class of heart medications called beta-blockers can have a helpful, or harmful, effect on the heart, depending on their molecular activity.

21 Nov 2009

NHLBI-supported research shares new strategies on hypertension, heart defect and air pollution

New education strategies for better controlling hypertension and research suggesting a possible link between short-term and long-term exposure to air pollution and increased risk of constricted blood vessels are among the research highlights from studies supported by the National Heart, Lung, and Blood Institute (NHLBI) at the American Heart Association's 2009 Scientific Sessions in Orlando held Nov. 14-18.

20 Nov 2009

Publicly released report cards do not appear to improve hospitals' performance, says new study

An analysis of quality of cardiac care following the public release of data on measures of care at hospitals in Ontario, Canada, did not result in significant systemwide improvement in hospitals' performance on most quality of care indicators, according to a study to be published in the December 2 issue of JAMA. The study is being released early online because of its presentation at an American Heart Association scientific conference.

19 Nov 2009

Drug therapy offers substantial cost savings than angioplasty

Many patients with diabetes should forego angioplasties for heart disease and just take medicine instead, according to a new National Institutes of Health study led by Stanford University School of Medicine researcher Mark Hlatky, MD.

18 Nov 2009

Mayo Clinic Health Letter provides treatment options for people with heart disorders

Fewer than one-third of patients with heart failure are taking the three types of medications that are most effective in prolonging life and improving quality of life. The November issue of Mayo Clinic Health Letter provides an overview of treatments recommended by national guidelines.

16 Nov 2009

Self-care tips for hemorrhoids from Mayo Clinic

By about age 50, more than half of adults have dealt with hemorrhoids. The November issue of Mayo Clinic Health Letter covers home treatments that can relieve symptoms of this common and embarrassing problem.

16 Nov 2009

Canadian cardiologists, oncologists team up to fight breast cancer

A team of Canadian cardiologists, in collaboration with oncologists, are playing an important role in the war against breast cancer Dr. Michael McDonald told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

26 Oct 2009

Boehringer Ingelheim receives European CHMP positive opinion for MICARDIS

Boehringer Ingelheim announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) has issued a positive opinion for the approval of MICARDIS® (telmisartan) for the reduction of cardiovascular morbidity.

23 Oct 2009

Canadian Cardiovascular Society to honor University of Alberta medical researcher

A University of Alberta medical researcher being hailed as a world leader in his field will receive a major national award for his pioneering work in the development of a new class of drugs for the treatment of heart failure.

23 Oct 2009

Two high blood pressure medicines effective in treating stable ischemic heart disease

Two medications commonly used to treat high blood pressure appear to be effective in treating a common type of heart disease known as stable ischemic heart disease, according to a new comparative effectiveness review funded by HHS' Agency for Healthcare Research and Quality.

20 Oct 2009

Boehringer Ingelheim's TWYNSTA approved by FDA for the treatment of hypertension

Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved TWYNSTA®, a new highly effective single pill combination therapy of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]). TWYNSTA® is indicated for the treatment of hypertension, alone or with other antihypertensive agents, and as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.